Roth Mkm Increases Zevra Therapeutics (NASDAQ:ZVRA) Price Target to $21.00

Zevra Therapeutics (NASDAQ:ZVRA) had its target price upped by Roth Mkm from $19.00 to $21.00 in a report issued on Tuesday morning, Benzinga reports. Roth Mkm currently has a buy rating on the stock.

A number of other equities analysts have also recently commented on the company. Maxim Group lifted their price target on Zevra Therapeutics from $18.00 to $25.00 and gave the stock a buy rating in a research note on Tuesday. JMP Securities started coverage on shares of Zevra Therapeutics in a research note on Tuesday. They issued an outperform rating and a $17.00 target price on the stock. HC Wainwright increased their price target on shares of Zevra Therapeutics from $18.00 to $20.00 and gave the company a buy rating in a research report on Friday, September 20th. William Blair upgraded shares of Zevra Therapeutics to a strong-buy rating in a research report on Friday, August 30th. Finally, Canaccord Genuity Group lowered their price objective on shares of Zevra Therapeutics from $24.00 to $22.00 and set a buy rating for the company in a research note on Wednesday, September 18th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of Buy and an average price target of $21.00.

Zevra Therapeutics Price Performance

ZVRA stock opened at $7.31 on Tuesday. The firm has a market cap of $384.65 million, a P/E ratio of -5.41 and a beta of 1.94. The firm’s fifty day moving average is $7.14 and its 200 day moving average is $5.76. Zevra Therapeutics has a 52 week low of $3.89 and a 52 week high of $8.95. The company has a debt-to-equity ratio of 1.80, a quick ratio of 2.00 and a current ratio of 2.00.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.01). Zevra Therapeutics had a negative net margin of 274.10% and a negative return on equity of 124.85%. The company had revenue of $4.45 million for the quarter, compared to the consensus estimate of $4.08 million. During the same period last year, the business posted ($0.15) earnings per share. Research analysts predict that Zevra Therapeutics will post -1.59 earnings per share for the current year.

Insider Buying and Selling at Zevra Therapeutics

In related news, Director Thomas Anderson bought 10,000 shares of the company’s stock in a transaction dated Tuesday, July 16th. The stock was purchased at an average cost of $6.81 per share, with a total value of $68,100.00. Following the transaction, the director now owns 20,000 shares in the company, valued at approximately $136,200. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In the last ninety days, insiders have purchased 22,000 shares of company stock valued at $140,340. 2.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. boosted its position in shares of Zevra Therapeutics by 3.6% during the first quarter. Vanguard Group Inc. now owns 1,704,006 shares of the company’s stock valued at $9,883,000 after purchasing an additional 58,866 shares in the last quarter. Retirement Planning Co of New England Inc. lifted its position in Zevra Therapeutics by 6.5% during the second quarter. Retirement Planning Co of New England Inc. now owns 458,300 shares of the company’s stock valued at $2,246,000 after buying an additional 28,107 shares during the period. Mystic Asset Management Inc. lifted its position in Zevra Therapeutics by 11.9% during the second quarter. Mystic Asset Management Inc. now owns 297,947 shares of the company’s stock valued at $1,460,000 after buying an additional 31,650 shares during the period. Armistice Capital LLC bought a new stake in shares of Zevra Therapeutics during the 4th quarter valued at $1,755,000. Finally, Bank of New York Mellon Corp grew its position in shares of Zevra Therapeutics by 10.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 220,499 shares of the company’s stock worth $1,080,000 after buying an additional 21,231 shares during the period. Hedge funds and other institutional investors own 35.03% of the company’s stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.